8-K: Lifeward Ltd. Announces Third Quarter 2024 Financial Results, Revenue Up 39%

Lifeward Ltd. reported a 39% increase in revenue for the third quarter of 2024, driven by strong sales of ReWalk systems and the launch of the AlterG NEO.

Summary

• Lifeward Ltd. announced its financial results for the third quarter ended September 30, 2024, showing a significant increase in revenue.
• The company's revenue reached $6.1 million, a 39% increase compared to $4.4 million in the same quarter of 2023.
• Revenue from historical products like ReWalk exoskeletons was $2.5 million, up 173% year-over-year, while AlterG product revenue was $3.6 million, a $0.7 million increase.
• Gross margin improved to 36.2% from 19.6% in the prior year, although non-GAAP adjusted gross margin decreased slightly to 42.5%.
• Operating expenses decreased to $5.4 million from $8.8 million year-over-year, and the operating loss improved to $3.2 million from $7.9 million.
• Net loss was $3.1 million, or $0.35 per share, compared to a net loss of $7.5 million, or $0.88 per share, in the third quarter of 2023.
• Lifeward has revised its full-year 2024 revenue guidance to $25 million to $26 million.
• The company had $10.7 million in unrestricted cash and cash equivalents with no debt as of September 30, 2024.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved profitability, but there are some concerns about non-GAAP gross margin and operating losses. The overall sentiment is positive but with some caution.

Positives

• Revenue growth was strong, with a 39% increase year-over-year.
• ReWalk sales saw a significant increase of 173% year-over-year.
• The launch of the AlterG NEO is proving successful, with 40 units ordered since June.
• Gross margin improved substantially to 36.2% from 19.6% year-over-year.
• Operating expenses decreased, leading to a reduced operating loss.
• Net loss per share improved from $0.88 to $0.35 year-over-year.
• The company has a strong cash position with $10.7 million in unrestricted cash and no debt.
• Lifeward is streamlining U.S. operations, expected to save $3 million in operating expenses and improve gross margins by two percentage points.
• The company is expanding AlterG sales through its German sales organization, leveraging existing infrastructure.

Negatives

• Non-GAAP adjusted gross margin decreased by 2.6 percentage points to 42.5% due to lower production volumes of AlterG systems and higher labor costs.
• Non-GAAP adjusted operating loss was $4.1 million, compared to a loss of $4.9 million in the third quarter of 2023.
• Cash used in operations was $4.5 million during the third quarter of 2024.
• The company has $2.4 million of accounts receivable for Medicare claims, a significant majority of which relates to claims filed before the third quarter of 2024.

Risks

• The conversion of ReWalk leads to revenue can be variable.
• The company faces risks associated with the integration of AlterG, including potential litigation and the ability to retain customers and key personnel.
• There are uncertainties associated with future clinical trials and the regulatory approval process.
• The company's ability to achieve reimbursement from third-party payors is crucial for its success.
• The company's limited operating history and reliance on third-party suppliers pose risks.
• Cybersecurity attacks and breaches of IT systems could significantly disrupt business operations.
• The company's ability to effectively use the proceeds of its offerings of securities is a risk.

Future Outlook

Lifeward has revised its full-year 2024 revenue guidance to $25 million to $26 million and expects sequential growth to resume in the fourth quarter, with the highest quarterly revenue of the year anticipated.

Management Comments

• Larry Jasinski, Chief Executive Officer, stated that the company continues to build the pipeline of ReWalk cases which they believe will fuel growth in future quarters.
• Larry Jasinski also noted that the AlterG NEO launch is stimulating incremental customer interest and growth, which they believe will fuel the anticipated recovery in AlterG revenue growth.

Industry Context

This announcement reflects a positive trend in the medical device industry, particularly in the rehabilitation sector, where companies are focusing on innovative technologies and expanding market access through insurance coverage. The company's focus on streamlining operations and expanding sales channels aligns with industry best practices.

Comparison to Industry Standards

• The 39% revenue growth is strong compared to many medical device companies, although specific comparisons are difficult without knowing the growth rates of direct competitors in the exoskeleton and anti-gravity rehabilitation space.
• The improvement in gross margin to 36.2% is a positive sign, but the non-GAAP adjusted gross margin decrease to 42.5% indicates potential challenges in production costs.
• Companies like Ekso Bionics and Cyberdyne, which also develop exoskeletons, may serve as benchmarks, but their financial results and market focus differ.
• The company's focus on Medicare reimbursement is a key factor, as successful navigation of this process can significantly impact revenue growth, similar to other companies in the medical device space.

Management Changes

Stakeholder Impact

• Shareholders will likely view the revenue growth and improved profitability positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to innovative rehabilitation solutions.
• Suppliers may see increased demand for their products.
• Creditors will be reassured by the company's improved financial performance.

Next Steps

• Lifeward will continue to focus on converting ReWalk leads into revenue.
• The company will continue to expand sales of AlterG products through its German sales organization.
• Lifeward will continue to monitor the performance of the AlterG NEO and its impact on revenue growth.
• The company will host a conference call to discuss its financial results on November 12, 2024.

Key Dates

Keywords

Lifeward, ReWalk, AlterG, Exoskeleton, Rehabilitation, Financial Results, Gross Margin, Operating Expenses, Net Loss, Medicare, Medical Devices